ARA-290 Price — Research Peptide Cost & Value (2026)

ARA-290 Price — Research Peptide Cost & Value (2026)

Research budgets don't fail because peptides are expensive—they fail because researchers purchase compounds that don't perform at the molecular level. A 2023 analysis published in Peptide Science found that nearly 40% of research-grade peptides purchased from non-verified suppliers showed sequence errors or contamination that rendered them functionally inactive. The ARA-290 price you see listed means nothing if the peptide doesn't bind to the erythropoietin receptor (EPO-R) with the specificity required for tissue protection studies.

We've supplied peptides to biological research teams across multiple disciplines for years. The gap between effective peptide procurement and wasted research funds comes down to three factors most purchasing agents never evaluate: amino acid sequence verification, lyophilisation quality, and third-party purity testing documentation.

What determines ARA-290 price in 2026 research markets?

ARA-290 price is primarily determined by synthesis method (solid-phase peptide synthesis versus recombinant), purity grade (≥95% versus ≥98%), batch size, third-party analytical verification (HPLC, mass spectrometry), and whether the supplier operates under cGMP manufacturing standards. Current 2026 pricing for research-grade ARA-290 ranges from $280 to $450 per 10mg vial, with higher pricing reflecting documented sequence fidelity and sterility testing rather than brand markup. The peptide is a synthetic 11-amino-acid sequence derived from the tissue-protective domain of erythropoietin, and even single-residue substitutions can eliminate receptor binding activity entirely.

Yes, ARA-290 price varies significantly between suppliers—but the variation isn't arbitrary. The molecule's mechanism depends on precise interaction with the innate repair receptor (IRR), a heterodimer of the EPO receptor and CD131. Peptides synthesized without rigorous quality control may contain deletion sequences, oxidized methionine residues, or incorrect stereochemistry at critical binding sites. The price difference between a verified peptide and an unverified one is the difference between reproducible results and failed experiments. This article covers exactly what drives ARA-290 price, what quality markers justify premium pricing, how to evaluate supplier claims, and which cost-cutting approaches compromise research integrity.

Understanding ARA-290 Price Drivers in Research Peptide Markets

The ARA-290 price you encounter reflects manufacturing complexity, not market positioning. ARA-290 is synthesized through solid-phase peptide synthesis (SPPS), a stepwise process where each amino acid is coupled sequentially to a growing peptide chain anchored to a resin. The 11-residue sequence requires 10 coupling cycles, each involving activation chemistry, deprotection steps, and washing protocols. Coupling efficiency below 99% at any step introduces deletion sequences—peptides missing one or more amino acids—that co-purify with the target product and reduce functional potency.

Purity grade is the primary ARA-290 price determinant. A ≥95% pure peptide priced at $280 per 10mg contains up to 5% impurities: truncated sequences, dimers, residual trifluoroacetic acid (TFA), or synthesis byproducts. A ≥98% pure peptide priced at $420 per 10mg has undergone additional HPLC purification runs to remove those contaminants. For mechanistic studies where receptor binding kinetics matter, that 3% purity difference is not academic—it directly affects the concentration of active peptide in your reconstituted solution. Third-party testing adds $40–$80 to ARA-290 price per batch but provides mass spectrometry confirmation of the correct molecular weight (1786.06 Da) and HPLC chromatograms showing single-peak purity.

Batch size inversely correlates with ARA-290 price. Custom synthesis of 50mg or 100mg quantities reduces per-milligram cost by 20–35% compared to 10mg vials because fixed costs (analytical testing, documentation, quality assurance) are amortized across larger output. However, peptide stability post-reconstitution limits the practical advantage—once mixed with bacteriostatic water, ARA-290 should be used within 28 days when refrigerated at 2–8°C. Purchasing a 100mg batch to save on ARA-290 price only makes sense if your research protocol will consume that volume within the stability window. Lyophilised powder stored at −20°C remains stable for 24–36 months, but reconstituted peptide degrades through oxidation and aggregation.

Supplier verification standards justify ARA-290 price premiums. Facilities operating under FDA-registered 503B outsourcing standards or cGMP (current Good Manufacturing Practice) environments incur higher compliance costs: environmental monitoring, personnel training, batch record documentation, sterility testing for every production run. These aren't marketing features—they're the systems that prevent cross-contamination, ensure sterile reconstitution environments, and create traceable accountability if a batch fails specification. A $150 price gap between two ARA-290 suppliers often reflects whether the peptide was synthesized in a validated cleanroom or a general chemistry lab.

Evaluating ARA-290 Price Against Quality Markers

ARA-290 price means nothing without corresponding quality documentation. The minimum acceptable standard for research-grade peptides includes a Certificate of Analysis (CoA) showing HPLC purity, mass spectrometry confirmation of molecular weight, and peptide content (mg of active peptide per mg of lyophilised powder). Suppliers who list ARA-290 price without providing batch-specific CoAs are selling compounds of unknown composition. HPLC chromatograms should show a single dominant peak representing the target peptide, with minor peaks (impurities) quantified and identified where possible. A purity specification of ≥98% means the target peak represents at least 98% of total UV absorbance at 220nm.

Mass spectrometry is non-negotiable for sequence verification. Electrospray ionisation mass spectrometry (ESI-MS) provides molecular weight confirmation to within ±1 Da, detecting synthesis errors like amino acid substitutions, deletions, or unexpected post-translational modifications. ARA-290's calculated monoisotopic mass is 1786.06 Da—if the CoA shows 1802 Da, the peptide contains an extra oxygen (oxidised methionine), which may alter receptor binding. If the CoA shows 1673 Da, a residue is missing entirely. Both scenarios render the peptide unsuitable for mechanistic studies, regardless of how competitive the ARA-290 price appears.

Peptide content percentage is the hidden variable in ARA-290 price comparisons. Lyophilised peptides contain residual water, counter-ions from synthesis (typically TFA salts), and in some cases bulking agents like mannitol. A vial labelled "10mg ARA-290" may contain only 7mg of actual peptide, with the remaining 3mg consisting of TFA and water. Reputable suppliers report peptide content as a percentage—if the CoA states 70% peptide content, you're paying ARA-290 price for 7mg of active compound, not 10mg. This is why per-milligram price calculations based solely on vial size are misleading. A $350 vial with 85% peptide content (8.5mg active) delivers better value than a $280 vial with 65% content (6.5mg active).

Sterility and endotoxin testing justify higher ARA-290 price in applications involving cell culture or ex vivo tissue models. Bacterial endotoxins (lipopolysaccharides from Gram-negative bacteria) activate immune responses at concentrations as low as 0.1 EU/mL, confounding inflammation and tissue protection studies. USP <85> Bacterial Endotoxins Test uses Limulus Amebocyte Lysate (LAL) assay to quantify endotoxin contamination—peptides intended for sterile research should report <1.0 EU/mg. Suppliers offering ARA-290 price below $250 per 10mg rarely perform endotoxin testing because the assay adds $60–$100 per batch. If your protocol involves primary cell cultures or organoid models, endotoxin contamination will invalidate results regardless of peptide purity.

ARA-290 Price: Research Applications and Dosing Economics

ARA-290 price per experiment depends on dosing requirements, which vary by research model. Published studies using ARA-290 for neuroprotection, wound healing, and metabolic research typically employ doses ranging from 1–10 µg per administration in vitro, or 0.5–4 mg/kg in rodent models. A 10mg vial reconstituted in 10mL bacteriostatic water yields a 1mg/mL stock solution. For in vitro work at 5 µg/mL final concentration in a 96-well plate (200 µL per well), one vial supports approximately 400 wells—translating to $0.70–$1.10 per well depending on ARA-290 price tier. For in vivo studies using 2mg/kg dosing in 250g rats, each injection requires 500 µg, meaning a 10mg vial provides 20 doses at $14–$22.50 per dose.

Dose-response characterisation drives ARA-290 price impact on research budgets. Establishing ED50 (effective dose for 50% maximal response) in a novel model requires testing 5–7 dose levels in triplicate across multiple timepoints. A single dose-response experiment in a 24-well format testing 1, 3, 10, 30, 100 µg/mL concentrations consumes 2–3mg of peptide—20–30% of a standard vial. Researchers who price-shop ARA-290 without accounting for experimental design often underestimate total peptide requirements, leading to mid-study reordering at higher per-unit cost or protocol modifications that compromise data integrity.

Storage and handling losses reduce effective yield from every vial purchased. Peptides adhere to plastic surfaces—transferring reconstituted ARA-290 between containers results in 5–15% loss depending on surface area contact. Low-binding microcentrifuge tubes (siliconised polypropylene) reduce adhesion but cost $0.30–$0.50 per tube versus $0.05 for standard tubes. Freeze-thaw cycles degrade peptide structure through ice crystal formation and pH shifts during thawing—aliquoting reconstituted peptide into single-use volumes prevents degradation but increases pipetting error and surface loss. These practical factors mean the usable peptide from a $400 vial may be 8–8.5mg rather than the nominal 10mg, effectively increasing real ARA-290 price by 15–20%.

Our experience supplying research labs indicates that peptide waste from improper reconstitution and storage exceeds waste from experimental use. ARA-290 synthesized through our small-batch process includes detailed reconstitution protocols and stability data because the ARA-290 price researchers pay should deliver maximum usable peptide, not maximum nominal mass. Every vial ships with batch-specific CoA, recommended storage conditions, and guidance on minimising handling losses—factors that turn a $400 peptide purchase into 95% usable yield rather than 75%.

ARA-290 Price: Supplier Comparison and Value Assessment

ARA-290 price varies across supplier categories: research chemical vendors, compounding pharmacies, peptide synthesis CROs (contract research organisations), and specialty peptide suppliers. Research chemical vendors typically offer the lowest ARA-290 price ($180–$280 per 10mg) but provide minimal documentation—CoAs may lack batch-specific data, mass spectrometry is rarely included, and customer support for technical questions is limited. These sources serve researchers conducting preliminary screens where peptide identity matters more than absolute purity, but they're unsuitable for mechanistic studies intended for publication.

Compounding pharmacies operating under FDA 503B registration offer ARA-290 price in the $320–$420 range with full analytical documentation, sterility testing, and cGMP manufacturing environments. These facilities produce peptides primarily for clinical research and investigational use, so quality systems are designed for regulatory scrutiny. The ARA-290 price premium reflects overhead costs of compliance, but it also provides assurance that the peptide contains what the label claims at the purity stated. For research groups preparing regulatory submissions or publishing in high-impact journals, the documentation trail justifies the cost difference.

Peptide synthesis CROs provide custom synthesis services with ARA-290 price determined by order size, purity specification, and delivery timeline. A 50mg custom order at ≥98% purity typically costs $1,200–$1,800 ($24–$36 per mg) with 4–6 week lead time, but provides full synthesis documentation, multiple analytical methods (HPLC, MS, amino acid analysis), and the ability to specify modifications like N-terminal acetylation or C-terminal amidation. Custom synthesis makes economic sense for research programs requiring ≥100mg total peptide or when standard commercial ARA-290 price doesn't include needed purity grades.

Specialty peptide suppliers like Real Peptides occupy the middle ground: ARA-290 price comparable to compounding pharmacies ($350–$450 per 10mg) with quality documentation, technical support, and inventory availability that CROs can't match. Our small-batch synthesis model produces peptides in 50–200mg lots, allowing us to maintain stock while performing full analytical characterisation on every batch. Researchers ordering ARA-290 receive peptide synthesized within the previous 60 days, not 12–18 month old inventory with unknown storage history. That freshness translates to higher functional activity because oxidation and aggregation occur even in lyophilised powder stored under ideal conditions.

The hidden cost in ARA-290 price comparison is failed experiments. A $150 savings on peptide procurement means nothing if the compound doesn't perform at the receptor level, forcing you to repeat the study with verified peptide—now you've spent $430 in peptide costs plus duplicated labour, reagents, and animal costs if applicable. We've consulted with research teams who spent $800 on low-cost ARA-290 across three suppliers before ordering verified peptide at $400 and finally achieving reproducible results. The effective ARA-290 price for that project was $1,200, not $400, because the initial "savings" produced no usable data.

Key Takeaways

• ARA-290 price ranges $280–$450 per 10mg in 2026, with variation reflecting synthesis quality, purity grade, and analytical verification rather than arbitrary markup.
• Purity specifications of ≥98% versus ≥95% represent measurable differences in functional peptide concentration—the 3% gap directly affects receptor binding studies.
• Peptide content percentage (typically 65–85%) means a 10mg vial contains 6.5–8.5mg active compound, making nominal ARA-290 price misleading without this specification.
• Mass spectrometry confirmation of 1786.06 Da molecular weight is the only reliable verification that synthesis produced the correct sequence—HPLC purity alone cannot detect amino acid substitutions.
• Sterility and endotoxin testing add $60–$100 to ARA-290 price per batch but are essential for cell culture applications where contamination confounds tissue protection mechanisms.
• Handling losses from peptide adhesion to plastic surfaces and freeze-thaw degradation reduce usable yield by 10–20%, effectively increasing real per-experiment cost regardless of purchase price.

What If: ARA-290 Price Scenarios

What If the ARA-290 Price Is Significantly Lower Than Market Average?

Verify purity documentation and peptide content before purchasing—prices below $250 per 10mg typically indicate ≤90% purity or lack third-party analytical verification. Request batch-specific CoA showing HPLC chromatogram and mass spectrometry data. If the supplier cannot provide these within 24–48 hours, the low ARA-290 price reflects unknown composition rather than competitive advantage. Peptides synthesized without rigorous quality control may contain deletion sequences (missing amino acids) that eliminate EPO receptor binding entirely, rendering the compound worthless regardless of cost savings.

What If Your Research Budget Cannot Accommodate Premium ARA-290 Price?

Prioritise analytical verification over volume purchased—10mg of verified ≥98% pure peptide delivers more usable data than 25mg of unverified material. Consider joining a consortium purchase with other research groups to access custom synthesis pricing ($24–$36 per mg for 50mg orders) while splitting costs. Adjust experimental design to reduce peptide consumption: microfluidic systems use 90% less peptide than traditional well plates, and in silico dose prediction can narrow the range tested experimentally. Never compromise on sequence verification to reduce ARA-290 price—a failed experiment costs more than the peptide itself when labour and reagent expenses are included.

What If the Supplier Offers ARA-290 Price Discounts for Bulk Orders?

Calculate total consumption within the 28-day post-reconstitution stability window before committing—purchasing 50mg to access 30% discount provides no value if only 15mg can be used before degradation. Lyophilised powder remains stable 24–36 months at −20°C, so bulk purchasing makes sense for established protocols with predictable consumption. Request extended dating documentation showing peptide stability beyond the standard specification. Verify that bulk pricing applies to the same purity grade and analytical package—some suppliers reduce ARA-290 price by substituting ≥95% purity for ≥98% without explicit disclosure.

The Transparent Truth About ARA-290 Price

Here's the honest answer: the research peptide market contains suppliers who know most purchasers cannot verify what they receive, and pricing strategies exploit that information asymmetry. ARA-290 price below $250 per 10mg almost always indicates compromised quality—either synthesis shortcuts that reduce purity, absence of analytical verification, or deliberately vague labelling where "10mg" refers to total powder mass rather than active peptide content. The lowest-cost supplier is rarely the lowest-cost-per-usable-result.

The bottom line: you're not buying milligrams of powder, you're buying a tool that must perform a specific molecular function. ARA-290 works by binding to the innate repair receptor with nanomolar affinity—single amino acid errors eliminate that binding. Paying $350 for peptide that works is infinitely better value than paying $200 for peptide that fails, because failed experiments consume time, labour, and opportunity cost that dwarf the peptide expense. Suppliers who transparently document synthesis quality, provide batch-specific analytics, and stand behind their products with technical support are worth the ARA-290 price premium. Those who compete solely on price are signalling that quality is negotiable.

The research community deserves better than treating peptides as commodity chemicals. ARA-290 represents years of medicinal chemistry optimising the tissue-protective domain of erythropoietin into an 11-residue sequence with clinical potential. That scientific achievement warrants synthesis and handling that preserves its molecular integrity. When evaluating ARA-290 price, ask not what the peptide costs but whether it will perform the function your research requires—and whether the supplier's quality systems provide reasonable confidence in that outcome.

If your protocol depends on ARA-290 binding to the EPO receptor with the specificity required for mechanistic studies, price becomes secondary to performance—and performance requires verified synthesis, confirmed purity, and documented stability. The ARA-290 price difference between low-cost and verified suppliers is $150–$200 per vial, but the cost difference between successful research and failed experiments is the entire project budget. Choose accordingly, and recognise that the cheapest option rarely delivers the lowest total cost of ownership.